Hepatocellular Carcinoma Clinical Trials in Pittsburgh, Pennsylvania

7 studies are recruiting for hepatocellular carcinoma in Pittsburgh, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

   This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in pa…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Pittsburgh, Pennsylvania

   Locations

   219 in total

   Run by

   AstraZeneca

   See if you can join NCT06921785 on ClinicalTrials.gov

2. Molecular Basis of Pediatric Liver Cancer

   The purpose of this retrospective and prospective project is to understand the molecular and genetic basis of liver cancer of childhood. Understanding the molecular and genetic bases of liver cancers can offer a better classification based on tumor biology, mechanisms and predisposition.

   Stage

   Not phased

   Ages

   0 to 99

   Site

   UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania

   Run by

   University of Pittsburgh

   See if you can join NCT03959800 on ClinicalTrials.gov

3. Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

   Patients with histologically or cytologically confirmed advanced melanoma, renal cell carcinoma, NSCLC, HCC (Child Pugh Class A only), MSI-High solid tumors, Urothelial Cancer, GE junction/Gastric Adenocarcinoma, or HNSCC for which current standard of care treatment for their stage of disease would…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

   Run by

   Dan Zandberg

   See if you can join NCT04114136 on ClinicalTrials.gov

4. Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

   The study will evaluate patient and Health Care Professional- reported preference for Subcutaneous (SC) compared with IV nivolumab administration or similarly for SC compared with IV pembrolizumab.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

   Run by

   Diwakar Davar

   See if you can join NCT07223424 on ClinicalTrials.gov

5. Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

   The purpose of this study is to assess the efficacy and safety of RP2 in combination with atezolizumab plus bevacizumab (Cohorts 1a and 1b) and RP2 monotherapy (Cohort 2) in the as second line treatment in patients with locally advanced unresectable, recurrent, and/or metastatic HCC and in combinat…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

   Locations

   12 in total

   Run by

   Replimune, Inc.

   See if you can join NCT05733598 on ClinicalTrials.gov

6. Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

   The investigators propose to evaluate the safety of drug combinations in patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies. Finding effective novel therapies for patients with advanced gastric cancer and other GI malignancies is an area of great unmet need.…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

   Locations

   2 in total

   Run by

   Anwaar Saeed

   See if you can join NCT03539822 on ClinicalTrials.gov

7. Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

   This study will investigate if modulating the tumor microenvironment with biologic agents like XL-092 will have synergistic effect when combined with checkpoint based immunotherapeutic treatment of patients with hepatocellular carcinoma (HCC).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

   Locations

   3 in total

   Run by

   Anwaar Saeed

   See if you can join NCT06698250 on ClinicalTrials.gov